Lipid Lowering and Incidence of Cataract, a Role for Fibrates
- 5 December 2018
- journal article
- editorial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (2) , 318-319
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Cariplo (2015‐0524, 2015‐0564)
- Horizon 2020 Framework Programme (PHC‐03‐2015/667837‐2)
This publication has 9 references indexed in Scilit:
- Use of Lipid‐Lowering Drugs and the Risk of Cataract: A Population‐Based Nested Case‐Control StudyClinical Pharmacology & Therapeutics, 2018
- Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysisJournal of Clinical Lipidology, 2018
- Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractEuropean Heart Journal, 2018
- CataractsThe Lancet, 2017
- Statin Use and the Risk of Cataracts: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association, 2017
- Statins and Cataracts—a Visual InsightCurrent Atherosclerosis Reports, 2014
- The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 DiabetesOphthalmology, 2014
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialThe Lancet, 2007